Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1810786 | 0.87 | TSHR (0.49) | KMT2ATDP1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1205875 | 0.87 | TDP1 (0.51) | KMT2ATDP1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL21268183 | 0.86 | CYP1A2 (0.44) | KMT2ATDP1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL6200854 | 0.86 | CHEK1 (0.41) | KMT2ATDP1HTTALDH1A1MAPT | |
| SCHEMBL6199939 | 0.84 | KMT2A (0.52) | KMT2ATDP1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL4318856 | 0.83 | TSHR (0.47) | KMT2AHTTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL2443988 | 0.83 | GAA (0.45) | KMT2ATDP1HTTALDH1A1MAPT | |
| SCHEMBL6195388 | 0.82 | KMT2A (0.38) | KMT2ATDP1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL6201377 | 0.82 | LIG1 (0.47) | SMN1; SMN2MAPTLMNAKDM4ETSHR | |
| SCHEMBL5400533 | 0.81 | SGMS2 (0.48) | KMT2AHTTMAPTLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202880-B2 | 3-hydroxy-6-phenylphenanthridines as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-7632844-B2 | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | NYCOMED GMBH (DE) | 2009-12-15 | — | — | US | disclosed |
| US-20090170892-A1 | 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors | NYCOMED GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20080319067-A1 | 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | NYCOMED GMBH | 2008-12-25 | — | — | US | disclosed |
| US-7423046-B2 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | NYCOMED GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7329676-B2 | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | NYCOMED GMBH (DE) | 2008-02-12 | — | — | US | disclosed |
| US-20070259909-A1 | Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors | ALTANA PHARMA AG (DE) | 2007-11-08 | — | — | US | disclosed |
| EP-1536798-B1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2007-02-07 | — | — | EP | disclosed |
| EP-1539164-B1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| EP-1725532-A1 | NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-29 | — | — | EP | disclosed |
| US-20050239818-A1 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | ALANA PHARMA AG (DE) | 2005-10-27 | — | — | US | disclosed |
| US-20050239817-A1 | 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | ALTANA PHARMA AG (DE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005085203-A1 | NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-15 | — | — | WO | disclosed |
| EP-1539164-A1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1536798-A1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004019945-A1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004019944-A1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239817-A1 | 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | PDE4A, PDE4B, PDE3A | KMT2A 1847/4885TDP1 60/4885HTT 2507/4885 |
| US-20070259909-A1 | Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors | PDE4A, PDE4B, PDE4D | KMT2A 1438/4885TDP1 145/4885HTT 2721/4885 |
| US-20080319067-A1 | 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | PDE4A, PDE4B, PDE3A | KMT2A 1847/4885TDP1 60/4885HTT 2507/4885 |
| US-20050239818-A1 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | PDE4A, PDE4B, PDE3A | KMT2A 2239/4885TDP1 62/4885HTT 2541/4885 |
| US-20090170892-A1 | 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors | PDE4A, PDE4B, PDE3A | KMT2A 2423/4885TDP1 62/4885HTT 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.